Compare ResMed Inc. (RMD) vs Silvercorp Metals Inc. Common Shares (SVM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Silvercorp Metals Inc. Common Shares — how do they compare? ResMed Inc. trades at $235.17 (market cap $32.99B), while Silvercorp Metals Inc. Common Shares trades at $9.5 (market cap $2.21B). The key difference: ResMed Inc. is far larger — about 14.9× Silvercorp Metals Inc. Common Shares's market cap, and ResMed Inc. pays the higher dividend (1.13%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Silvercorp Metals Inc. Common Shares for 0 Days on average.
| RMD | SVM | |
|---|---|---|
Market Cap | $32.99B | $2.21B |
Volume | 1,023,381 | 1,113,327 |
Sector | Health | Basic Materials |
52-Week High | $275.96 | $15.71 |
52-Week Low | $182.82 | $6.09 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $32.35B | $1.94B |
Dividend Yield | 1.13% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $235.29, up 0.29% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 27.2% net margins and consistent earnings beats in recent quarters. Recent news highlights include upcoming Q1 2027 earnings and management presentations at healthcare conferences, while analyst consensus remains positive with a $243.56 price target.
RMD presents a favorable investment case with strong profitability metrics and positive earnings momentum, though elevated valuation ratios and ongoing legal investigations warrant caution. The stock's technical strength supports near-term upside potential toward resistance levels, while fundamental growth drivers in sleep therapy demand provide long-term support.
Silvercorp Metals (SVM) trades at $10.03, down 2.62% on the day, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue grew significantly from $299M in 2025 to $495M in 2026, though net income margin compressed. Analyst consensus is 60% buy with no sell ratings. Recent news highlights expansion into Ecuador and Kyrgyzstan to diversify geographic risk and a renewed share repurchase program.
The outlook is cautiously optimistic, driven by production expansion and strong operational cash flow, but tempered by execution risks in new jurisdictions and margin pressure. Key opportunities include global growth initiatives and efficient cost structure, while risks involve geopolitical exposure and volatile metal prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Silvercorp Metals Inc. Common Shares
Silvercorp Metals Inc. is a Canadian mining company that operates underground silver-lead-zinc mines and processing plants in China, with additional exploration projects in Ecuador.
Read more on SVM →
